ABIVAX announces an update on its share capital and voting rights

On February 23, 2024, ABIVAX (Euronext Paris: FR0012333284 - ABVX), a biotechnology company focused on developing treatments for chronic inflammatory diseases, disclosed the number of shares making up its share capital as well as the total count of its voting rights as of January 31, 2024. The company's capital amounts to €629,288.18, represented by 62,928,818 shares. In terms of voting rights, the theoretical total stands at 69,938,767, while the number of exercisable voting rights is 69,927,438.

Through this announcement, ABIVAX complies with regulatory requirements regarding financial transparency, providing a clear view to shareholders and the market. This update highlights the company's governance structure and its commitment to following the recommendations of the French Financial Markets Authority (Autorité des Marchés Financiers). ABIVAX continues its development, notably with its flagship drug, obefazimod (ABX464), actively in phase 3 for the treatment of ulcerative colitis.